Matrix Biomed, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.matrixbiomed.com
Clinical Trials
6
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (100.0%)Treatment of Metastatic Cancer in Terminally Diagnosed Patients
- Conditions
- Metastatic Cancer
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Matrix Biomed, Inc.
- Registration Number
- NCT05491928
- Locations
- 🇺🇸
UCHealth University of Colorado Cancer Center - Anschutz Medical Campus, Aurora, Colorado, United States
MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia
Phase 2
- Conditions
- Ataxia Telangiectasia Louis-BarAtaxia Telangiectasia in ChildrenAtaxia Telangiectasia
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Matrix Biomed, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04887311
- Locations
- 🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States
MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer
Phase 2
- Conditions
- Prostate Cancer RecurrentBiochemical Recurrent Prostate Cancer
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Matrix Biomed, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04876755
- Locations
- 🇺🇸
Prostate Oncology Specialists, Marina Del Rey, California, United States
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Matrix Biomed, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04874506
- Locations
- 🇺🇸
Georgetown, Washington, District of Columbia, United States
A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Matrix Biomed, Inc.
- Registration Number
- NCT04337099
- Locations
- 🇺🇸
Prostate Oncology Specialists, Marina Del Rey, California, United States
- Prev
- 1
- 2
- Next
News
No news found